Fetal nigral transplantation as a therapy for Parkinson's disease

C. W. Olanow, J. H. Kordower, T. B. Freeman

Research output: Contribution to journalReview articlepeer-review

435 Scopus citations


Fetal nigral grafts have been demonstrated to survive, secrete dopamine, form synaptic connections with host neurons, and reverse behavioral disturbances in experimental models of parkinsonism. These findings suggest that fetal nigral grafting may be a useful therapy for patients with Parkinson's disease (PD). Recent preliminary clinical trials of transplantation in PD have shown increased striatal fluorodopa uptake (measured using positron emission tomography) and clinical benefit in some patients. An autopsy study of one patient who had received fetal nigral transplants demonstrated robust graft survival and striatal reinnervation, with no evidence of host-derived sprouting or immune rejection. The development of a successful clinical transplantation program depends on a careful consideration of the transplantation variables and the related long-term risks and benefits to the patients.

Original languageEnglish (US)
Pages (from-to)102-109
Number of pages8
JournalTrends in Neurosciences
Issue number3
StatePublished - Mar 1996
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Fetal nigral transplantation as a therapy for Parkinson's disease'. Together they form a unique fingerprint.

Cite this